{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:49:54Z","timestamp":1780393794981,"version":"3.54.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"27-28","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1016\/j.vaccine.2004.03.026","type":"journal-article","created":{"date-parts":[[2004,4,10]],"date-time":"2004-04-10T11:53:41Z","timestamp":1081598021000},"page":"3738-3743","source":"Crossref","is-referenced-by-count":29,"title":["ISCOMATRIX\u2122 adjuvant: an adjuvant suitable for use in anticancer vaccines"],"prefix":"10.1016","volume":"22","author":[{"given":"Trina J","family":"Stewart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Drane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Malliaros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Elmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M","family":"Malcolm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stirling J","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian H","family":"Frazer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germain J.P","family":"Fernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vaccine.2004.03.026_BIB1","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jcp.55.4.244","article-title":"The causal relation between human papillomavirus and cervical cancer","volume":"55","author":"Bosch","year":"2002","journal-title":"J. Clin. Pathol."},{"issue":"5","key":"10.1016\/j.vaccine.2004.03.026_BIB2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/(SICI)1097-0215(19960301)65:5<601::AID-IJC8>3.0.CO;2-6","article-title":"Human papillomavirus\u2014the most significant risk determinant of cervical intraepithelial neoplasia","volume":"65","author":"Kjaer","year":"1996","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.vaccine.2004.03.026_BIB3","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc798","article-title":"Papillomaviruses and cancer: from basic studies to clinical application","volume":"2","author":"zur Hausen","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.vaccine.2004.03.026_BIB4","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1128\/JVI.63.10.4417-4421.1989","article-title":"The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes","volume":"63","author":"Munger","year":"1989","journal-title":"J. Virol."},{"key":"10.1016\/j.vaccine.2004.03.026_BIB5","first-page":"217","article-title":"Immune response to human papillomaviruses and the prospects for human papillomavirus-specific immunisation","volume":"186","author":"Tindle","year":"1994","journal-title":"Curr. Top Microbiol. Immunol."},{"issue":"3","key":"10.1016\/j.vaccine.2004.03.026_BIB6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/BF01240612","article-title":"Saponin adjuvants. Part 3. Isolation of a substance from Quillaja saponaria Molina with adjuvant activity in food-and-mouth disease vaccines","volume":"44","author":"Dalsgaard","year":"1974","journal-title":"Arch. Gesamte. Virusforsch."},{"issue":"17\u201319","key":"10.1016\/j.vaccine.2004.03.026_BIB7","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1016\/S0264-410X(00)00497-7","article-title":"Immune responses to ISCOM formulations in animal and primate models","volume":"19","author":"Sjolander","year":"2001","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2004.03.026_BIB8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1440-1711.1998.00756.x","article-title":"Functional aspects of iscoms","volume":"76","author":"Morein","year":"1998","journal-title":"Immunol. Cell. Biol."},{"issue":"5","key":"10.1016\/j.vaccine.2004.03.026_BIB9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1046\/j.1365-3083.1998.00327.x","article-title":"Vaccine-induced Th1-type responses are dominant over Th2-type responses in the short term whereas pre-existing Th2 responses are dominant in the longer term","volume":"47","author":"Fernando","year":"1998","journal-title":"Scand. J. Immunol."},{"issue":"2","key":"10.1016\/j.vaccine.2004.03.026_BIB10","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2249.1995.tb08349.x","article-title":"A vaccine conjugate of \u2018ISCAR\u2019 immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants","volume":"101","author":"Tindle","year":"1995","journal-title":"Clin. Exp. Immunol."},{"issue":"3","key":"10.1016\/j.vaccine.2004.03.026_BIB11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1046\/j.1365-2249.1999.00813.x","article-title":"Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16","volume":"115","author":"Fernando","year":"1999","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.vaccine.2004.03.026_BIB12","first-page":"343","article-title":"Design of a candidate recombinant therapeutic vaccine for cervical cancer","volume":"1","author":"Edwards","year":"1998","journal-title":"Recent Res Develop Biotechnol Bioeng"},{"issue":"1","key":"10.1016\/j.vaccine.2004.03.026_BIB13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000024959","article-title":"T cell-mediated and non-specific inflammatory mechanisms contribute to the skin pathology of HPV 16 E6E7 transgenic mice","volume":"42","author":"Hilditch-Maguire","year":"1999","journal-title":"Intervirology"},{"issue":"5","key":"10.1016\/j.vaccine.2004.03.026_BIB14","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.4049\/jimmunol.161.5.2421","article-title":"Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model","volume":"161","author":"Fernando","year":"1998","journal-title":"J. Immunol."},{"issue":"15","key":"10.1016\/j.vaccine.2004.03.026_BIB15","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/0264-410X(95)00029-Z","article-title":"Peptide polymerisation facilitates incorporation into ISCOMs and increases antigen-specific IgG2a production","volume":"13","author":"Fernando","year":"1995","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2004.03.026_BIB16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0168-1702(94)00101-H","article-title":"T-helper epitopes of the E7 transforming protein of cervical cancer associated human papillomavirus type 18 (HPV18)","volume":"36","author":"Fernando","year":"1995","journal-title":"Virus Res."},{"issue":"12","key":"10.1016\/j.vaccine.2004.03.026_BIB17","first-page":"3058","article-title":"Inhibition of early tumor growth requires J alpha 18-positive (natural killer T) cells","volume":"63","author":"Stewart","year":"2003","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.vaccine.2004.03.026_BIB18","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1073\/pnas.95.2.652","article-title":"Fc receptors are required in passive and active immunity to melanoma","volume":"95","author":"Clynes","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.vaccine.2004.03.026_BIB19","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0169-409X(98)00013-1","article-title":"ISCOMs and other saponin based adjuvants","volume":"32","author":"Cox","year":"1998","journal-title":"Adv. Drug. Deliv. Rev."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X04002695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X04002695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T07:26:32Z","timestamp":1682666792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X04002695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":19,"journal-issue":{"issue":"27-28","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S0264410X04002695"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2004.03.026","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}